Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy

Among patients with symptomatic obstructive hypertrophic cardiomyopathy, treatment with aficamten led to a greater increase in peak oxygen consumption than placebo at 6 months.

​   The New England Journal of Medicine: Search Results in Cardiology